A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.
Mikio SugimotoYoshiyuki KakehiShigeo HorieYoshihiko HiraoHideyuki AkazaPublished in: Japanese journal of clinical oncology (2021)
In patients with low-risk prostate cancer, low-dose chlormadinone showed a reduced number of positive cores and prostate volume, and an increased persistence rate of active surveillance (UMIN000012284).